Overview

M6620 First in Human Study

Status:
Completed

Trial end date:
2020-03-11

Target enrollment:

Participant gender:

Summary

An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics (PK) of M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors

Phase:

Phase 1

Details

Lead Sponsor:

EMD Serono Research & Development Institute, Inc.
Vertex Pharmaceuticals Incorporated

Collaborator:

Merck KGaA, Darmstadt, Germany

Treatments:

Carboplatin
Cisplatin
Etoposide
Etoposide phosphate
Gemcitabine
Irinotecan